BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE Drug Patent Profile
Which patents cover Betamethasone Acetate And Betamethasone Sodium Phosphate, and when can generic versions of Betamethasone Acetate And Betamethasone Sodium Phosphate launch?
Betamethasone Acetate And Betamethasone Sodium Phosphate is a drug marketed by Am Regent and Hikma and is included in two NDAs.
The generic ingredient in BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE is betamethasone acetate; betamethasone sodium phosphate. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the betamethasone acetate; betamethasone sodium phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Betamethasone Acetate And Betamethasone Sodium Phosphate
A generic version of BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE was approved as betamethasone acetate; betamethasone sodium phosphate by AM REGENT on July 31st, 2009.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE?
- What are the global sales for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE?
- What is Average Wholesale Price for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE?
Summary for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 3 |
| Patent Applications: | 88 |
| DailyMed Link: | BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE at DailyMed |
Recent Clinical Trials for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Shehab Ahmed Hamad | PHASE3 |
| Tel-Aviv Sourasky Medical Center | N/A |
| Edward Kasaraskis | Early Phase 1 |
See all BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE clinical trials
Pharmacology for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Am Regent | BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE | betamethasone acetate; betamethasone sodium phosphate | INJECTABLE;INJECTION | 090747-001 | Jul 31, 2009 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Hikma | BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE | betamethasone acetate; betamethasone sodium phosphate | INJECTABLE;INJECTION | 077838-001 | Jan 17, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
